Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$115.04
pos +0.00
+0.00%
Today's Range: 114.91 - 116.49 | GILD Avg Daily Volume: 10,904,000
Last Update: 07/02/15 - 4:00 PM EDT
Volume: 0
YTD Performance: 22.05%
Open: $0.00
Previous Close: $116.01
52 Week Range: $84.75 - $123.37
Oustanding Shares: 1,469,605,980
Market Cap: 169,063,471,939
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 10 11
Moderate Buy 3 3 3 3
Hold 1 1 3 2
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.47 1.47 1.68 1.56
Latest Dividend: 0.43
Latest Dividend Yield: 1.50%
Dividend Ex-Date: 06/12/15
Price Earnings Ratio: 13.10
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
13.10 13.10 26.10
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
16.87% 32.08% 345.59%
GROWTH 12 Mo 3 Yr CAGR
Revenue 122.20 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
EBITDA 16.32B
Revenue 24.89B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $2.83 $2.72 $11.04 $9.56
Number of Analysts 1 1 1 1
High Estimate $2.83 $2.72 $11.04 $9.56
Low Estimate $2.83 $2.72 $11.04 $9.56
Prior Year $2.32 $1.79 $7.91 $11.04
Growth Rate (Year over Year) 21.98% 51.96% 39.57% -13.41%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Jun 29, 2015 | 12:10 PM EDT

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

By

Chris Laudani

 | Jun 24, 2015 | 1:00 PM EDT

The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.

By

Jim Cramer

 | Jun 23, 2015 | 5:25 AM EDT

As long as this keeps happening, don't stay away.

By

Robert Lang

 | Jun 22, 2015 | 10:00 AM EDT

I like BioMarin because it has more upside and solid Relative Strength.

By

Bret Jensen

 | Jun 19, 2015 | 7:23 AM EDT
It's great to be filling for Doug Kass at the end of a trading week.
By

Bret Jensen

 | Jun 16, 2015 | 1:15 PM EDT

Caution should trump fear of missing out on further gains.

By

Jim Cramer

 | Jun 11, 2015 | 2:18 PM EDT

New companies are coming up with major drugs.

By

Jim Cramer

 | Jun 4, 2015 | 11:40 AM EDT

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

By

Jim Cramer

 | Jun 3, 2015 | 11:32 AM EDT

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

By

Bret Jensen

 | Jun 2, 2015 | 2:00 PM EDT

Use this strategy to avoid leaving money on the table.

If the adage that the market hates uncertainty, then a "yes" vote just brings further nego...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.